Back to Search Start Over

FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

Authors :
Garam N
Cserhalmi M
Prohászka Z
Szilágyi Á
Veszeli N
Szabó E
Uzonyi B
Iliás A
Aigner C
Schmidt A
Gaggl M
Sunder-Plassmann G
Bajcsi D
Brunner J
Dumfarth A
Cejka D
Flaschberger S
Flögelova H
Haris Á
Hartmann Á
Heilos A
Mueller T
Rusai K
Arbeiter K
Hofer J
Jakab D
Sinkó M
Szigeti E
Bereczki C
Janko V
Kelen K
Reusz GS
Szabó AJ
Klenk N
Kóbor K
Kojc N
Knechtelsdorfer M
Laganovic M
Lungu AC
Meglic A
Rus R
Kersnik Levart T
Macioniene E
Miglinas M
Pawłowska A
Stompór T
Podracka L
Rudnicki M
Mayer G
Rysava R
Reiterova J
Saraga M
Seeman T
Zieg J
Sládková E
Stajic N
Szabó T
Capitanescu A
Stancu S
Tisljar M
Galesic K
Tislér A
Vainumäe I
Windpessl M
Zaoral T
Zlatanova G
Józsi M
Csuka D
Source :
Frontiers in immunology [Front Immunol] 2021 Sep 10; Vol. 12, pp. 720183. Date of Electronic Publication: 2021 Sep 10 (Print Publication: 2021).
Publication Year :
2021

Abstract

Background: Factor H-related protein 5 (FHR-5) is a member of the complement Factor H protein family. Due to the homology to Factor H, the main complement regulator of the alternative pathway, it may also be implicated in the pathomechanism of kidney diseases where Factor H and alternative pathway dysregulation play a role. Here, we report the first observational study on CFHR5 variations along with serum FHR-5 levels in immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) patients together with the clinical, genetic, complement, and follow-up data.<br />Methods: A total of 120 patients with a histologically proven diagnosis of IC-MPGN/C3G were enrolled in the study. FHR-5 serum levels were measured in ELISA, the CFHR5 gene was analyzed by Sanger sequencing, and selected variants were studied as recombinant proteins in ELISA and surface plasmon resonance (SPR).<br />Results: Eight exonic CFHR5 variations in 14 patients (12.6%) were observed. Serum FHR-5 levels were lower in patients compared to controls. Low serum FHR-5 concentration at presentation associated with better renal survival during the follow-up period; furthermore, it showed clear association with signs of complement overactivation and clinically meaningful clusters.<br />Conclusions: Our observations raise the possibility that the FHR-5 protein plays a fine-tuning role in the pathogenesis of IC-MPGN/C3G.<br />Competing Interests: Author VJ was employed by company Medimpax. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Garam, Cserhalmi, Prohászka, Szilágyi, Veszeli, Szabó, Uzonyi, Iliás, Aigner, Schmidt, Gaggl, Sunder-Plassmann, Bajcsi, Brunner, Dumfarth, Cejka, Flaschberger, Flögelova, Haris, Hartmann, Heilos, Mueller, Rusai, Arbeiter, Hofer, Jakab, Sinkó, Szigeti, Bereczki, Janko, Kelen, Reusz, Szabó, Klenk, Kóbor, Kojc, Knechtelsdorfer, Laganovic, Lungu, Meglic, Rus, Kersnik Levart, Macioniene, Miglinas, Pawłowska, Stompór, Podracka, Rudnicki, Mayer, Rysava, Reiterova, Saraga, Seeman, Zieg, Sládková, Stajic, Szabó, Capitanescu, Stancu, Tisljar, Galesic, Tislér, Vainumäe, Windpessl, Zaoral, Zlatanova, Józsi and Csuka.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
34566977
Full Text :
https://doi.org/10.3389/fimmu.2021.720183